摘要
肺癌已经成为目前癌症死亡的首要原因,近年来研究发现LKB1在非小细胞肺癌中LKB1体细胞突变率仅次于p53、K-ras突变率,尤其在NSCLC中其突变率甚至高达15%~35%。LKB1主要抑癌机制是可以引起细胞周期阻滞在G0/G1期,阻碍或延缓细胞DNA的合成,从而抑制细胞生长。研究者们发现LKB1的缺失突变在促进肺癌组织类型的分化和肺癌转移中扮演着相当重要的角色,因此动态检测LKB1是否异常可用于肺癌早期发生、发展及判断预后,并可能成为肺癌的恶性程度及预后因子。本文对近年来关于LKB1在肺癌领域中的研究进展作一综述。
Lung cancer has become the leading cause of cancer death. In recent years, it has been found that the mutation rate of LKB1 in non small cell lung cancer cells is only second to p53, K-ras mutation rate, especially in NSCLC, which is even as high as 15% -35%. LKB1 anticancer mechanism is to induce cell cycle arrest in G0/GI phase, inhibit or delay the synthesis of DNA cells, and inhibit cell growth. The researchers found that the deletion mutation of LKB1 plays an important role in promoting the differentia- tion and metastasis of lung cancer tissue. Therefore, the dynamic testing of LKB1 anomalies can be used to diagnose the occurrence, development and prognosis of lung cancer and it may become the malignant degree index and prognostic factor of lung cancer. In this paper, the research progress of LKB1 in the field of lung cancer in recent years is reviewed.
出处
《辽宁医学院学报》
CAS
2016年第4期104-107,共4页
Journal of Liaoning Medical University (LNMU) Bimonthly
关键词
肺癌
LKB1
诊断
治疗
lung cancer
LKB1
diagnosis
treatment
